Grant of Options

RNS Number : 4915Z

SkinBioTherapeutics PLC

18 September 2020

 

18 September 2020

SkinBioTherapeutics plc

("SkinBioTherapeutics" or "the Company" or "the Group")

Grant of Options
 

SkinBioTherapeutics plc (AIM: SBTX), a life science company focused on skin health, announces that the Company has granted a total of 1,809,695 options to subscribe for new ordinary shares in the Company under the SkinBioTherapeutics Share Option Program to Professor  Catherine O'Neill, Chief Scientific Officer and Stuart Ashman, CEO both PDMRs of the Company on 3 March and 8 April 2020 respectively (the "Options").  Following an internal review of announcements it was noted that no notification had been made at the time of the relevant grants in accordance with article 19(3) of the Market Abuse Regulation and this announcement corrects this omission.

The Options for Professor O'Neill have vested with immediate effect, are exercisable at a price of 9.5p per share and will expire on 3 March 2030.

The Options for Mr Ashman can be exercised no earlier than 24 months from the date of grant and are subject to achieving performance milestones set by the Company's board which are aligned to growth in shareholder value and commercialisation of the Company's technology. The Options are exercisable at a price of 9p per share and will expire on 8 April 2030.

The following options have been granted to Directors and PDMRs:

	Director	Number of options granted	Total number of options
	Catherine O'Neill	512,334	4,404,416
	Stuart John Ashman	1,297,361	5,189,444

SkinBioTherapeutics plc Stuart J. Ashman, CEO Doug Quinn, CFO	Tel: [phone]
Cenkos Securities Plc (Nominated Adviser & Broker) Giles Balleny, Max Gould (Corporate Finance) Michael Johnson (Sales)	Tel: [phone]
Instinctif Partners Melanie Toyne-Sewell / Phillip Marriage / Nathan Billis	Tel: [phone] [e-mail]

T he below makes the following disclosures in accordance with article 19(3) of the Market Abuse Regulation:

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1	Details of the person discharging managerial responsibilities/person closely associated
a.	Name	Professor Catherine O'Neill
2	Reason for notification	Grant of share options
a.	Position/Status	Chief Scientific Officer
b.	Initial notification/ Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.	Name	SkinBioTherapeutics Plc
b.	LEI	213800YMQOCB23FX6I06
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.	Description of the financial instrument, type of instrument Identification Code	Share options for ordinary shares of 1p each   ISIN: GB00BF33H870
b.	Nature of the transaction	Grant of share options
c.	Price(s) and volume(s)
			Price(s) per share	Volume(s)
			9.5p	512,334
d.	Aggregated information - Aggregated Volume - Price	n/a
e.	Date of the transaction	3rd March 2020
f.	Place of the transaction	O ff market
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1	Details of the person discharging managerial responsibilities/person closely associated
a.	Name	Stuart John Ashman
2	Reason for notification	Grant of share options
a.	Position/Status	Chief Executive Officer
b.	Initial notification/ Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.	Name	SkinBioTherapeutics Plc
b.	LEI	213800YMQOCB23FX6I06
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.	Description of the financial instrument, type of instrument Identification Code	Share options for ordinary shares of 1p each   ISIN: GB00BF33H870
b.	Nature of the transaction	Grant of share options
c.	Price(s) and volume(s)
			Price(s) per share	Volume(s)
			9.0p	1,297,361
d.	Aggregated information - Aggregated Volume - Price	n/a
e.	Date of the transaction	8th April 2020
f.	Place of the transaction	O ff market

 

END

 

 

DSHBUGDCLSBDGGI